Meeting
2021 ASCO Annual Meeting
Germline testing and somatic tumor testing for BRCA1/2 pathogenic variants in ovarian cancer: What is the optimal sequence of testing?
Authors
Janice S. Kwon
University of British Columbia, Vancouver, BC, Canada
Janice S. Kwon , Anna Tinker , Jennifer Santos , Katie Compton , Sophie Sun , Kasmintan A. Schrader , Aly Karsan
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Prevention, Risk Reduction, and Hereditary Cancer
Track
Prevention, Risk Reduction, and Genetics
Sub Track
Germline Genetic Testing
Citation
J Clin Oncol 39, 2021 (suppl 15; abstr 10585)
DOI
10.1200/JCO.2021.39.15_suppl.10585
Abstract #
10585
Poster Bd #
Online Only
Abstract Disclosures
Similar Posters
Poster
2020 Gastrointestinal Cancers Symposium
Case series examining somatic test results for patients with hereditary cancer syndromes associated with gastrointestinal cancer risk.
First Author: Kristen Pauley
Poster
2017 ASCO Annual Meeting
Evaluating the cost-effectiveness of current FDA-approved PARP inhibitors for the treatment of recurrent ovarian cancer.
First Author: Juliet Elizabeth Wolford
Poster
2016 ASCO Annual Meeting
A Markov model to evaluate cost-effectiveness of the PARP inhibitor, olaparib, for fourth line treatment of recurrent ovarian cancer.
First Author: Juliet Elizabeth Wolford
Poster
2023 ASCO Annual Meeting
Cost-effectiveness analyses of population-based multi-gene testing for the prevention of breast and ovarian cancer in the United States.
First Author: Fangjian Guo